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Needle-Based Ablation of Renal Parenchyma 
Using Microwave, Cryoablation, Impedance- and
Temperature-Based Monopolar and Bipolar Radiofrequency,
and Liquid and Gel Chemoablation: Laboratory Studies and
Review of the Literature
JAMIL REHMAN, M.D.,1 JAIME LANDMAN, M.D.,2 DAVID LEE, M.D.,3
RAMAKRISHNA VENKATESH, M.D.,2 DAVID G. BOSTWICK, M.D.,4
CHANDRU SUNDARAM, M.D.,5 and RALPH V. CLAYMAN, M.D.3
ABSTRACT
Background and Purpose: Small renal tumors are often serendipitously detected during the screening of pa-
tients for renal or other disease entities. Rather than perform a radical or partial nephrectomy for these
diminutive lesions, several centers have begun to explore a variety of ablative energy sources that could be
applied directly via a percutaneously placed needle-like probe. To evaluate the utility of such treatment for
small renal tumors/masses, we compared the feasibility, regularity (consistency in size and shape), and re-
producibility of necrosis produced in normal porcine kidneys by different modes of tissue ablation: mi-
crowaves, cold impedance-based and temperature-based radiofrequency (RF) energy (monopolar and bipo-
lar), and chemical. Chemoablation was accomplished using ethanol gel, hypertonic saline gel, and acetic acid
gel either alone or with simultaneous application of monopolar or bipolar RF energy.
Materials and Methods: A total of 107 renal lesions were created laparoscopically in 33 domestic pigs. Mi-
crowave thermoablation (N 5 12) was done using a Targis T3 (Urologix) 10F antenna. Cryoablation (N 5 16)
was done using a single 1.5-mm probe or three 17F microprobes (17F SeedNet™ system; Galil Medical) (N 5
10 single probe and N 5 6 three probes); a double freeze cycle with a passive thaw was employed under ul-
trasound guidance. Dry RF lesions were created using custom-made 18-gauge single-needle monopolar probe
with two or three exposed metal tips (GelTx) (N 5 12) or a single-needle bipolar probe (N 5 6) at 50 W of
510 kHz RF energy for 5 minutes. In addition, a multitine RF probe (RITA Medical Systems) was used in
one set of studies (N 5 6). Both impedance- and temperature-based RF were evaluated. Chemoablation was
performed with 95% ethanol (4 mL), 24% hypertonic saline (4 mL), and 50% acetic acid (4 mL) as single in-
jections. In addition, chemoablation was tested with monopolar and bipolar RF (wet RF). Tissues were har-
vested 1 week after ablation for light microscopy.
Results: In 11 of the 15 ablation techniques, there was complete necrosis in all lesions; however, three eth-
anol gel lesions had skip areas, three hypertonic saline gel lesions showed no necrosis or injury, and one
monopolar RF and one bipolar RF lesion showed skip areas. In contrast to impedance-based RF, heat-based
RF (RITA) caused complete necrosis without skip areas. All cryolesions resulted in complete tissue necrosis,
and cryotherapy was the only modality for which lesion size could be effectively monitored using ultrasound
imaging.
1Department of Urology, School of Medicine, SUNY-Stony Brook University, Stony Brook, New York.
2Department of Surgery, Division of Urologic Surgery, Washington University School of Medicine, St. Louis, Missouri.
3Department of Urology, School of Medicine, University of California, Irvine, California.
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INTRODUCTION
WIDESPREAD APPLICATION OF CT and abdominal ul-trasonography has led to an increase in the detection of
small localized solid renal masses.1–4 These renal masses are
associated with a significant clinical dilemma, as 20% to 30%
are benign. Unfortunately, percutaneous biopsy of these small
lesions is unreliable. Indeed, Zincke and associates, who
prospectively analyzed 106 intraoperative renal biopsies, found
the overall accuracy to be only 76% to 80%, with 22% of the
lesions being benign.5
Accordingly, except in the elderly or extremely high-risk pa-
tient, excisional surgery is usually selected. Traditionally, these
patients have been treated with radical nephrectomy 1,2,6 or,
more recently, nephron-sparing surgery.1,7–15 However, in
agreement with Bell’s original work more than 70 years ago, a
recent series by Walther and colleagues showed that no tumor
,3 cm was associated with metastasis.16 For these small le-
sions, the current literature suggests that with partial nephrec-
tomy, crude and cause-specific survival is comparable to those
obtained with radical nephrectomy for small (#4 cm), low-
grade, low-stage renal-cell carcinoma out to 10 years.17 Con-
cerns over satellite lesions are certainly valid for larger tumors;
however, the incidence of satellite malignant lesions when the
primary lesion is #3 cm is only 3.7%.18
In an effort to decrease the morbidity of open nephron-spar-
ing surgery, laparoscopic partial nephrectomy and wedge exci-
sion of small renal masses have been reported; however, these
techniques are still in their earliest stages. Moreover, they are
often lengthy and require a high degree of skill on the part of
the laparoscopic surgeon. In contrast, recent reports of laparo-
scopic needle ablative surgery, using predominantly cryother-
apy or, less commonly, radiofrequency (RF) energy, have been
shown to result in a less complex, yet apparently effective, ab-
lative procedure. Even less invasive than the laparoscopic ap-
proach are needle-based therapies using MR or CT guidance
for needle placement and treatment monitoring. The advantages
of percutaneous needle ablation include minimal morbidity, low
cost, suitability for real-time imaging guidance, and the appro-
priateness for performance in an outpatient setting.
To evaluate the effectiveness of needle ablative therapy in
the kidney, we compared the regularity and reproducibility of ne-
crosis produced in normal porcine kidneys by several energy
sources: microwave thermotherapy (MT), cryotherapy, monopo-
lar and bipolar single-needle RF using both impedance- and tem-
perature-controlled monitoring, multitine monopolar RF, and
monopolar and bipolar RF combined with ethanol, acetic acid,
or hypertonic saline gel infusion. In addition, each of the three
gels was tested as an ablative therapy in its own right.
MATERIALS AND METHODS
General approach
Laparoscopic procedure: A series of 33 female domestic
pigs (50–70 kg) were used. After being anesthetized, the pigs
were placed in a 30° Trendelenburg supine position, and pneu-
moperitoneum was achieved with a Veress needle via an in-
fraumbilical puncture. A 12-mm laparoscopic port was placed
via this incision, and a 10-mm laparoscope was inserted. The
pig was rearranged in the lateral decubitus position, and under
direct vision, two more 12-mm trocars were inserted in the mid-
axillary line above and below the level of the umbilicus. The
upper and lower poles of the kidney were dissected. Just prior
to the delivery of any needle-based ablative energy, surgical
sponges were placed around the kidney to help prevent dam-
age to adjacent visceral structures. The sponges were inserted
and removed through a 12-mm port.
Tissue harvesting and histopathologic examination: The
animals were sacrificed 1 week after ablative therapy, and their
kidneys were harvested. This time frame was selected to per-
mit analysis of the destructive effects of each modality at the
cellular level. The abdominal cavity was explored to rule out
any damage to other organs and to identify any adhesions. Both
kidneys were removed for anatomic and histologic evaluation.
Gross measurements of the field of ablation were made in three
dimensions (length, width, and depth) using calipers after each
kidney had been bivalved through the center of the treated field.
All sections were fixed in 10% Formalin, sectioned, and em-
bedded in paraffin. Hematoxylin and eosin (H&E) staining was
performed. The size of the lesion, completeness of ablation, ev-
idence of complications, and viability of the remainder of the
kidney were assessed. Histopathologic analysis was performed
by a skilled genitourinary tract pathologist (DJB).
Cryotherapy
Animals: Seven pigs were used in this study.
Cryosurgical system and temperature monitoring: Cryo-
probes were from the 17-gauge SeedNet™ system (Galil Med-
ical, Yokneam, Israel); the needles were constructed to be used
with argon gas (Fig. 1). This system consisted of a computer work-
station, a gas gauge, a gas distribution system, and accessories in-
cluding needle-like cryoprobes, temperature sensors, and a remote
control device. It used high-pressure cooling gas (argon), which
achieved temperatures as low as 2185°C at the tip of the needle
probes.19 To thaw the tissues rapidly, a high-pressure gas (helium)
was converted to a warm low-pressure gas. Each cryoprobe was
equipped with a thermocouple that monitored needle-tip temper-
ature throughout freezing and thawing. A computer interface dis-
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Conclusions: Cryoablation and thermotherapy produce well-delineated, completely necrotic renal lesions.
The single-probe monopolar and bipolar RF produce limited areas of tissue necrosis; however, both are en-
hanced by using hypertonic saline, acetic acid, or ethanol gel. Hypertonic saline gel with RF consistently pro-
vided the largest lesions. Ethanol and hypertonic saline gels tested alone failed to produce consistent cellular
necrosis at 1 week. In contrast, RITA using the StarburstTM XL probe produced consistent necrosis, while
impedance-based RF left skip areas of viable tissue. Renal cryotherapy under ultrasound surveillance pro-
duced hypoechoic lesions, which could be reasonably monitored, while all other modalities yielded hypere-
choic lesions the margins of which could not be properly monitored with ultrasound imaging.
played needle-tip temperatures and was used to specify the de-
sired temperature during the procedure. Heat exchange occurred
only along a 4-cm segment at the distal end of each cryoprobe.
Three cryoprobes can be used simultaneously in one or more lo-
cations and frozen or thawed independently. Separate trials were
done with both a single- and a three-probe array.
Delivery of cryotherapy: The needles were inserted from an-
terior (ventral) to posterior (dorsal) under transperitoneal laparo-
scopic and ultrasound guidance (Tetrad US system). All probes
were inserted to a depth of 7 to 8 mm to avoid entering the col-
lecting system. The needle tips are echogenic, allowing their
placement to be monitored by ultrasonography. The progress of
the cryoablation was easily monitored by observing the advance
of the iceball’s hyperechoic rim. Cryoprobes were placed through
the skin or a laparoscopic port. Thermosensors were also inserted
into the renal parenchyma at 3-mm intervals (six sites per kid-
ney) so that data would be collected both within and beyond the
iceball. When a three-probe array was used, the needles were
placed sufficiently close to one another to allow the iceballs to
overlap. Freezing was measured continuously. Two freeze-thaw
cycles (15-minute freeze, 10-minute passive thaw) were used.
During freezing, the cryoprobe tip temperatures reached a nadir
of 2140° to 2160°C. After the second freeze, the probes were
retracted. Overall, 16 lesions were created, 10 with a single probe
and 6 with the three-probe array.
Microwave thermotherapy
Animals: Three pigs were used.
Microwave thermotherapy control unit and heating an-
tenna (end-fed gamma-matched helical dipole antenna): A
modified MT system (Targis T3; Urologix, Minneapolis, MN)
was utilized to deliver controlled microwave energy via a mi-
crowave antenna (Fig. 2). The system generator output has a
maximum of 60 W at 1296 MHz. The control unit fiberoptic,
as well as a resistive thermal device, “RTD,” was used to mon-
itor intralesional temperatures as well as the temperature around
the antenna in real time. For this particular experiment, power
was adjusted to achieve between 80° and 95°C adjacent to the
antenna, which typically required 10 to 20 W. The device we
used was a 10F, 2-cm long bare antenna. The treatment dura-
tion was 15 minutes. Twelve kidney lesions were created (two
lesions per kidney in both the upper and the lower poles).
Placement of heating antenna and creation of lesion: The
antenna was placed in the kidney parenchyma under ultrasound
guidance, being careful to avoid entry into the collecting system.
Radiofrequency energy using single-needle monopolar
and bipolar electrode probes
Animals: Five pigs were used.
Radiofrequency system and temperature-monitoring
equipment and technique: An RF generator (Valleylab IIC
electrosurgical generator) with an output of 50 W at 500 kHz
was used. Separate laparoscopic needle electrodes (18-gauge,
2 cm of exposed metal distal tip [Prosurg/Injectx, San Jose,
CA]) were used for monopolar and bipolar RF (Fig. 3). Ground-
ing for the monopolar trials was achieved by attaching a dis-
persive pad to the pig’s buttock (surface area .400 cm2). The
needle electrode was then connected to the RF generator. In the
bipolar electrode, the active and receiving portions were spaced
1 cm apart on the shaft of the needle. These RF needle were
impedance based for their regulation. 
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FIG. 1. Cryotherapy system (Galil™) uses 17 F cryotherapy
needle probes (SeedNet™).
FIG. 2. Urologix T3 microwave system with antenna.
Placement of needle electrodes and creation of lesion: For
each treatment session, a single RF needle electrode was posi-
tioned at the center of the area to be ablated. The RF energy
was delivered at 50 w at 500 kHz for 5 minutes. Generator out-
put was slowly increased (over 2 minutes), so the tissue im-
pedance increased very slowly. During RF, a hyperechoic area
was observed around the electrode tip; after RF delivery
stopped, the hyperechoic area slowly disappeared. A total of 12
monopolar and 6 bipolar lesions were created with the single
needle electrode.
Chemoablative with and without monopolar and
bipolar RF
Animals: Fifteen pigs were used.
Placement of needles and creation of lesion by hypertonic
saline, ethanol, and acetic acid: A hollow insulated laparo-
scopic monopolar or bipolar RF needle electrode (18-gauge 2-
cm exposed metal tip [GelTx™; ProsurgeInjectex]) was placed
in a predetermined area of the renal parenchyma under direct
laparoscopic and ultrasound guidance for infusion of the spe-
cific gel. Hypertonic saline, ethanol, or acetic acid gel was in-
fused through the needle electrode during ablation using the
same RF settings (50 W at 500 kHz for 5 minutes) as were used
for the aforedescribed plain RF trials. Generator output was
slowly increased (over 2 minutes), so the tissue impedance in-
crease slowly. Before activation of the electrode, 1 mL of hy-
pertonic saline (23.4%), ethanol (95%), or acetic acid (50%)
gel was injected; after activation of RF, continuous infusion of
the selected chemoablative gel through the needle electrode into
the renal parenchyma was continued at 2 mL/min (total 4 mL)
into the area to be ablated. Ultrasonography (Tetrad system)
was used to image the kidney before treatment, during injec-
tion, and after ablation, imaging being performed with a high-
frequency 10-MHz transducer. During injection, a hyperechoic
area was observed around the electrode tip; the patch progres-
sively enlarged. After the treatment, the hyperechoic area
slowly disappeared. Seven lesions were created with hypertonic
saline gel (23.4%) and six each with ethanol gel (95%), acetic
acid gel (50%), hypertonic saline gel with monopolar RF, hy-
pertonic saline gel with bipolar RF, ethanol gel with monopo-
lar RF, ethanol gel with bipolar RF, acetic acid gel with
monopolar RF, and acetic acid gel with bipolar RF.
Heat-based radiofrequency energy
Animals: Three pigs were used.
Placement of probe and creation of lesion: The RF probe
(StarBurst™ XL; RITA Medical Systems, Mountain View, CA)
was designed to create a 3- or 5-cm lesion in the liver with 10
or 30 minutes of RF application, respectively (Fig. 4). For 3-
cm lesions, the lateral tines are 2.5 apart, while for a 5-cm le-
sion, the lateral tines are 4.5 cm apart. The probe was placed
under laparoscopic and ultrasound guidance; it was deployed
under ultrasound guidance (Prosound™ 5000; Aloka Co.,
Wallingford, CT). Tissues were heated to .100°C for 10 min-
utes using a Valleylab System 1500 with real-time temperature
monitoring from five thermocouples within the array. The de-
velopment of the lesion was monitored continuously with in-
tracorporeal ultrasonography. To prevent bleeding, the needle
track was closed using the track ablation mode of the system
at the end of the procedure. Six lesions were created; one in
each of the six kidneys. The tissues were harvested at 1 week
and stained with H&E for histologic examination.
RESULTS
Cryotherapy
All animals completed the 1–week protocol. At sacrifice and
harvest, various degrees of adhesions and inflammation were
present on the kidney surface. Occasionally, some bowel ad-
hesions were present at the site of the cryoablation, but no bowel
damage was noted. There was no hemorrhage or urinoma.
Gross pathology: The capsule over the treatment site was
thickened, occasionally wrinkled, and adherent to the underly-
ing renal parenchyma. After removal of the renal capsule, the
gross appearance of the lesion was regular. The treated paren-
chyma was grayish-white with a surrounding area of erythema-
tous parenchyma for a few millimeters that merged into normal
renal parenchyma. When the kidney was bivalved, it was noted
that there was loss of the corticomedullary junction. The lesions
were circular on the surface of the kidney and stopped at the re-
nal pelvis. In a few animals, the renal pelvis was slightly thick-
ened and pale but with no apparent erosion or perforation. The
single-needle lesions averaged 33.0 (length) 3 8.2 (breadth) 3
8.2 mm (depth). The three-needle lesions averaged 23.5 3 20.3 3
13.9 mm (Table 1).
Histologic findings: Each lesion consisted of a wedge-
shaped area of coagulative necrosis in the renal cortex and
medulla extending to the renal pelvis (Fig. 5). The overlying
renal capsule was thickened and fibrotic. There was a relatively
abrupt transition (1–2 mm) at the border of the lesion from the
necrotic to the viable tissue. The 1- to 2-mm intervening area
revealed partial necrosis with hemorrhage, glomerular conges-
tion and atrophy, segmental sclerosis, tubular necrosis, and cap-
illary thrombosis. In the area of coagulative necrosis, there was
a complete lack of cellular details for all kidney substructures
extending from the renal capsule to the collecting ducts in the
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FIG. 3. Single RF needle electrode (A) monopolar and (B)
bipolar.
papilla. The urothelium of the renal pelvis revealed mucinous
metaplasia in all animals. (Unlike the human, mucinous meta-
plasia of the urothelium is a common finding in the porcine
model. In one animal, the urothelium was partially necrotic but
still intact.) The margin of each of the lesions was infiltrated
with polymorphonuclear leukocytes and some lymphocytes.
Microwave thermotherapy
All animals completed the 1-week protocol. At sacrifice and
harvest, there were very few peritoneal adhesions. There were
no adhesions between the bowel and the treated area.
Gross pathology: The lesion sites were smooth; the capsule
was thickened and focally adherent to the underlying paren-
chyma. The lesion was grayish-white to yellow with a thin rim
of surrounding pinkish renal parenchyma, which merged into
normal parenchyma. There was evidence of some hemorrhage
and a hole at the antennae site. The bivalved kidney revealed
complete loss of the corticomedullary junction at the lesion site.
The lesions were circular, extending equidistant from the an-
tennae; the lesions extended to, but not through, the renal pelvis.
The average lesion size was 22.0 3 17.3 3 11.0 mm (Table 1).
Histologic findings: There was coagulative necrosis in the
renal cortex and medulla extending to the level of the renal
pelvis (Fig. 6). The overlying renal capsule was slightly thick-
ened by fibrosis. There was a very thin (#1-mm) transition zone
from the necrotic to the viable tissue. The urothelium of the re-
nal pelvis was intact in all the animals. The necrotic zone at the
margin of the lesion was infiltrated by polymorphonuclear
leukocytes along with some lymphocytes.
Radiofrequency energy
All animals completed the 1–week protocol. Bubbles of gas
and, occasionally, sparking from the electrosurgical probe were
noted during activation of monopolar or bipolar RF; ultra-
sonography during RF revealed transient hyperechoic areas. At
harvest, dense adhesions were consistently present on the renal
surface. The peritoneum was also adherent at the site of the le-
sions. Occasionally, bowel was adherent at the renal treatment
site. One pig had a urinoma.
Gross pathology: The site of the lesion was rough, thick,
and adherent to the renal capsule. The lesions were pale yel-
low on the surface. There was some charring along the needle
tract after both monopolar and bipolar RF. Within the lesion,
there was loss of the corticomedullary junction. The lesion ex-
tended up to, but not into, the renal pelvis. With monopolar RF
(N 5 12), the lesions averaged 8.1 3 6.6 3 7.4 mm, while with
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FIG. 4. Heat-based RF system and StarBurst XL probe.
bipolar RF (N 5 6), the lesions averaged 7.4 3 6.4 3 6.2 mm
(Table 1).
Histologic findings: Each lesion consisted of a wedge-
shaped area of focal coagulative necrosis extending broadly
from the renal cortex and the medulla to a narrower area at the
level of the renal pelvis. In each case, the renal capsule over-
lying the lesion was firmly adherent and fibrotic. The lesions
displayed a central zone of necrosis with a rim of inflamma-
tion (2–3 mm) and fibrosis at the border between the necrotic
and viable tissue (Figs. 7 and 8). There was tubular hypere-
osinophilia and nuclear smudging with relative sparing of the
glomeruli at the margin. One monopolar RF and one bipolar
RF lesion contained skip areas of viable tissue.
Chemoablation with and without monopolar and
bipolar RF
All animals completed the 1–week protocol after use of hy-
pertonic saline gel with or without RF. At sacrifice and har-
vest, a few peritoneal adhesions were present on the kidney sur-
face. There was no adherence between the bowel and the treated
area. Occasionally, there was evidence of leakage of gel along
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TABLE 1. SIZES OF ABLATIVE LESIONS CREATED WITH DIFFERENT MODALITIES
Length Breadth Depth Complete
Technique No. (mm 6 SE) (mm 6 SE) (mm 6 SE) necrosis (%)
Microwaves (Urologix) 12 21.97 6 2.12 17.25 6 1.46 10.91 6 0.35 12 (100)
Cryotherapy single microprobe 10 8.33 6 0.47 8.22 6 0.52 8.22 6 0.32 10 (100)
(Galil)
Cryotherapy three microprobes 6 23.5 6 1.73 20.25 6 1.87 13.87 6 0.72 6 (100)
(Galil)
RF (monopolar) 12 8.14 6 1.33 6.57 6 0.72 7.43 6 0.92 11 (91.6)
RF (bipolar) 6 7.44 6 1.02 6.44 6 0.37 6.22 6 0.57 5 (83.3)
Ethanol gel (95%) 6 4.8 6 1.06 4 6 0.31 4.6 6 1.12 3 (50)
Ethanol gel 1 monopolar RF 6 12.2 6 1.96 10 6 0.31 8.0 6 0.83 6 (100)
Ethanol gel 1 bipolar RF 6 10 6 0.51 9.66 6 0.33 7.66 6 0.56 6 (100)
Hypertonic saline gel (23.4%) 7 2.33 6 0.33 2 6 0.0 1.66 6 0.34 3 (50)
Hypertonic saline 1 monopolar RF 6 27 6 4.37 22.2 6 3.47 12.4 6 1.69 6 (100)
Hypertonic saline 1 bipolar RF 6 21 6 2 16.80 6 1.82 12.2 6 2.03 6 (100)
Acetic acid gel (50%) 6 14.4 6 3.31 11.80 6 2.53 7.4 6 1.03 6 (100)
Acetic acid 1 monopolar RF 6 21.25 6 2.05 17.25 6 2.13 9.87 6 0.95 6 (100)
Acetic acid 1 bipolar RF 6 20.33 6 0.33 14 6 3.05 9 6 0.58 6 (100)
Heat-based RITAa 6 25.8 6 0.20 23.1 6 0.26 12.5 6 0.11 6 (100)
aMeasurements in cm.
FIG. 5. Effects of cryoablation. (A) Lesion consists of coagulative necrosis of renal cortex and medulla. (B) Margin of cry-
olesion. There is relatively abrupt (1- to 2-mm) transition from necrotic to viable tissue. In this transition zone, there is partial
necrosis with hemorrhage, glomerular congestion, and capillary thrombosis.
A B
the needle tract, especially when the needle was withdrawn
quickly (the first two lesions created). To create the remaining
lesions, we modified our surgical technique such that the nee-
dle was left in place for several minutes after gel injection and
then slowly withdrawn; this maneuver seemed to limit or pre-
vent back leakage of the gel. Leakage of hypertonic saline from
the needle tract during RF activation caused superficial linear
burn injuries to the renal surface.
Gross pathology: The lesions were cone shaped and irreg-
ular; in general, they were larger on the surface of the kidney
and smaller toward the renal pelvis. The largest lesions were
achieved using hypertonic saline gel with monopolar RF
(27.0 3 22.2 3 12.4 mm) followed by hypertonic saline gel
with bipolar RF (21.0 3 16.8 3 12.2 mm) (Table 1). The le-
sions created by hypertonic saline gel alone were small (2.33
6.0.33 mm) and pale yellow.
Histologic findings: Each lesion consisted of a wedge-
shaped area of focal coagulative necrosis extending broadly
from the renal cortex and the medulla to a narrower area at the
level of the renal pelvis (Fig. 9). The renal capsule overlying
the lesion was normal after use of hypertonic saline alone, but
after concomitant delivery of monopolar or bipolar RF energy,
it was slightly thickened (Fig. 10). In three hypertonic saline
lesions, there were skip areas of viable tissue; but there was
complete necrosis with hypertonic saline injection plus
monopolar or bipolar RF activation.
All animals treated with ethanol gel alone or with monopo-
lar or bipolar RF completed the 1-week protocol. Occasionally,
there had been leakage of ethanol gel along the needle tract.
Serum ethanol concentrations at were 15.9 6 1.80 mg/dL 1
hour and 11.8 6 1.64 mg/dL at 3 hours. At harvest, marked
peritoneal adhesions were present on the renal surface. In three
animals, bowel was adherent to the treated area.
Gross pathology: Ethanol lesions were grossly wedge
shaped, with irregular borders; the lesions were larger on the
surface of the kidney and smaller toward the renal pelvis. Eth-
anol gel with monopolar RF produced lesions averaging 12.2 3
10 3 8.0 mm, while the lesions produced by ethanol gel with
bipolar RF were slightly smaller: 10 3 9.7 3 7.7 mm. The le-
sions created by ethanol gel alone were only 4.8 3 4 3 4.6 mm
(Table 1).
Histologic findings: Each lesion consisted of a wedge-
shaped area of focal coagulative necrosis extending broadly
from the renal cortex and the medulla to a narrower area at the
level of the renal pelvis (Fig. 11). The renal capsule was slightly
thickened in all cases, especially after treatment with monopo-
lar or bipolar RF (Fig. 12). In three ethanol gel lesions, there
were skip areas of viable tissue, but there was complete necro-
sis when monopolar or bipolar RF activation had also been used.
Occasionally, when RF was used with ethanol, there were
flames or smoke.
All animals treated with acetic acid gel with or without
monopolar or bipolar RF completed the 1-week protocol. At
sacrifice and harvest, marked peritoneal adhesions were pres-
ent on the renal surface. In all animals, bowel was adherent to
the treated renal surface. Occasionally, there was evidence of
leakage of acetic acid gel along the needle tract. Arterial blood
gas measurements were performed 1 and 3 hours after each pro-
cedure; the anion gap remained in the normal range, albeit in
the upper region.
Gross pathology: Lesions created by acetic acid gel alone
averaged 14.4 3 11.8 3 7.4 mm. Acetic acid gel with monopo-
lar RF produced larger lesions: 21.3 3 17.3 3 17.3 mm, as did
acetic acid gel combined with bipolar RF: 20.3 314 3 9 mm
(Table 1).
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FIG. 6. Effects of microwave thermotherapy. Coagulative ne-
crosis is seen in renal cortex and medulla with complete loss
of details. Transition zone from necrotic to viable tissue is very
thin (#1mm).
FIG. 7. Effects of monopolar RF energy. Lesions display cen-
tral zone of necrosis with 2- to 3-mm rim of inflammation and
fibrosis at the border between necrotic and viable tissue. Some
viable cells are seen (arrow).
Histologic findings: The lesions produced were irregular in
shape, larger on the surface of the kidney and smaller toward
the renal pelvis. In all cases, with and without RF energy, the
acetic acid gel was associated with complete necrosis without
skip areas (Figs. 13 and 14). Acetic acid dissolved the renal
capsule at the site of treatment and at any site of extravasation.
Heat-based RF treatment
All animals completed the 1-week protocol. At sacrifice and
harvest, a few peritoneal adhesions were present on the kidney
surface. In one animal, bowel was adherent to the treated area.
The deployment of the needles was satisfactory in all six kid-
neys. On ultrasound imaging, the prongs were identified as hy-
perechoic dots; lesions were seen as hyperechoic areas ema-
nating from the tips of the prongs.
Gross pathology The renal capsule overlying the lesion was
firmly adherent and fibrotic. The lesions created averaged 2.6 3
2.3 3 1.3 cm (Table 1). The lesions were circular and pale yel-
low (Fig. 15). Within the lesion, there was loss of the corti-
comedullary junction. The lesion extended into the renal pelvis.
Histologic findings: There was complete necrosis with no
skip areas, extending broadly from the renal cortex and the
medulla (Fig. 16). The microscopic margin of the lesion was
slightly dentate. There was a 2- to 3-mm rim of inflammation
around the area of necrosis.
DISCUSSION
Cryotherapy
In urology, liquid nitrogen-based cryotherapy was first used
in the 1960s for the treatment of prostate cancer20; however, it
was abandoned because of the high complication rate secondary
to failure to properly image probe placement prior to initiating
the freezing process.21 With the creation of argon-based
cryosystems and the development of ultrasound imaging,
cryotherapy has been reintroduced as a treatment for prostate
cancer and small renal tumors. The new argon gas-based
cryosurgical systems reach target temperatures quickly, and ul-
trasound monitoring allows real-time tracking of the freezing
process. Although used in some centers, renal cryotherapy is
still in its developmental phase. In this study, we used the small-
est available cryoprobe (1.5 mm or 17 gauge) and applied it to
the normal porcine kidney.
Mechanism of cryoinjury: Intense rapid freezing results in
cellular death by several mechanisms.22 Cell death during the
freezing cycle has several causes: (1) a combination of intra-
cellular and extracellular ice-crystal formation with subsequent
rupture of plasma membranes, intracellular membranes, and or-
ganelles; (2) cellular dehydration; (3) protein denaturation; (4)
hypoxia; (5) solute shifts; (6) uncoupling of oxidative phos-
phorylation; and (7) vascular thrombosis. In areas close to the
cryoprobe, temperatures rapidly approach 2165° to 2190°C,
depending on probe size. Farther away from the probe, tem-
peratures drop less dramatically because of the vascular-based
heat-sink effect; still, damage to tissue occurs because the cool-
ing solutes are excluded from the forming ice, making the ex-
tracellular fluid hypertonic. As a result, nonfrozen tissue suf-
fers damage secondary to the chemical gradient induced by
dehydration. During the thaw cycle, additional tissue damage
occurs as a result of acute vascular injury and the resulting 
hypoxia. Indeed, during the thaw cycle, smaller blood vessels
rupture secondary to the chemical gradient that occurs within
nonfrozen tissue. There is progressive damage to the microcir-
culation, resulting in hypoxia, endothelial cell damage, edema,
and platelet aggregation with thrombosis and further vascular
occlusion, all culminating in enhanced ischemic necrosis. In
sum, whereas near the cryoprobe, extremely cold temperatures
cause lethal intracellular ice crystal formation, at the periphery
of the iceball, osmotic effects predominate.23–25
Intralesional temperature and tissue necrosis: It is gen-
erally accepted that the critical temperature to ensure cancer
cell destruction is approximately 240°C.26,27 It is postulated
that a longer duration of freezing, repeated freeze-thaw cycles,
and a longer thaw period may provide equal results at a slightly
higher temperature.22 Chosy and coworkers28 used thermosen-
sors to monitor the effects of cryotherapy on the kidney and
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FIG. 8. Effects of bipolar RF energy. Lesions display central
zone of necrosis with 1- to 3-mm rim of inflammation and fi-
brosis at border between necrotic and viable tissue. Some vi-
able cells remain (arrow).
FIG. 9. Effects of hypertonic saline. Focal coagulative ne-
crosis is apparent. There were skip areas of viable tissue in
three of six lesions (50%).
were able to corroborate the effectiveness of 220°C provided
the freeze cycle lasted 15 minutes and a double-freeze tech-
nique was employed. Other factors that influence the size of
the cryolesion include the area of contact between the cryoprobe
and the targeted tissue and tissue vascularity. Increased blood
flow creates a heat sink that may distort, while it slows, the
symmetric growth of the iceball.34 Of note, ex vivo ureteropye-
lograms and renal arteriograms in swine have demonstrated oc-
clusive amputation of the collecting system and the vasculature
of the ablated renal segment.29
During the first freeze, the rate and degree of blood flow are
the most important determinants of the progress of the iceball.
During subsequent freezes, changes in tissue-specific heat have
a greater impact on the iceball size. While it may thus seem
reasonable to clamp the renal artery during cryotherapy, oc-
clusion of the renal blood flow does not in fact enhance the size
of the cryolesion to a significant extent. Indeed, an intact cir-
culation may protect the collecting system from injury.30 There-
fore, we did not occlude the blood supply of the kidney during
our renal cryoablation trials.
Typically, the cryolesion develops very rapidly at first; in-
deed, most of the growth of the iceball occurs in the initial 5
minutes. Of note, while some studies have employed only a 5-
minute freeze, other studies have shown that it takes approxi-
mately 20 minutes for the iceball to reach a steady state.31
Area of necrosis: It is important to determine the exact lo-
cation within the iceball where reproducible and complete tis-
sue necrosis occurs. During cryotherapy, incremental increases
in temperature occur from the center toward the periphery of
the lesion. As such, the advancing outer edge of the iceball is
approximately 0°C, too high to cause cell death.24 It is not un-
til 4 to 6 mm inside the periphery of the iceball that the tem-
perature is in the 220°C to 240°C range that is necessary for
tissue necrosis.32,33 Accordingly, it is important that the edge
of the cryolesion, as seen laparoscopically and ultrasonography,
extend approximately 1 cm beyond the visible margin of the
targeted tumor.34–36
Fortunately, it appears that the renal pelvis is relatively re-
sistant to cryotherapy. In our study, only one of seven animals
had partial necrosis of the renal pelvis, and there was no defect
or urinoma formation. These findings are similar to those of
others,37 who showed the effect of cryotherapy on the renal
pelvis to be minimal. An acute lesion with sloughing of the
urothelium and the lamina propria was noted; however, when
animals were sacrificed at 1 month, there had been regrowth of
the urothelium and lamina propria. This finding suggests that
cryoablation could be used safely for hilar and centrally located
renal tumors, but it remains unknown whether sufficient ne-
crosis would occur because of the problem of the significant
heat sink effect provided by the major renal vasculature in this
area.
Because of the small size of the cryoprobes we used (i.e.,
1.4 mm), we used both a single and multiple probes to see if
the latter would allow the creation of larger lesions without skip
areas. The three-probe deployment resulted in faster freezing
with a reduction in the transition zone of ischemia and an al-
most threefold greater volume of treated area. However, even
with triple-probe deployment, the lesion created was ,8 cc, in-
sufficient to fully treat a 2-cm lesion. We believe that if per-
cutaneous therapy is to be effective, multiple-needle cryoprobes
will be needed, perhaps as many as four to six on a template.
Histopathology findings: Sequential histologic changes af-
ter renal cryoablation are myriad. Within 1 hour, interstitial
hemorrhage with vascular congestion is noted, accompanied by
extravasation of red blood cells into the injured parenchyma
and coagulative necrosis. At 1 week, four distinct zones are
seen: central necrosis, inflammatory infiltrate, hemorrhage, and
fibrosis.38–40 Healing from cryoablation is gradual, occurring
by secondary intention with steady fibrotic contracture of the
involved area that produces a wedge-shaped chronic le-
sion.28,38,41,42 At 1 week, we noted ischemic coagulative ne-
crosis with a relatively abrupt (1- to 2-mm) transition from
necrotic to viable tissue at the border of the lesion. There was
hemorrhage in the transition zone. The urothelium of the renal
pelvis was partially necrotic in one pig, but no urinoma formed.
Urothelium in the renal pelvis showed evidence of mucinous
NEEDLE-BASED ABLATION OF RENAL PARENCHYMA 91
FIG. 10. Effects of hypertonic saline and monopolar RF en-
ergy. Each lesion consists of wedge-shaped area of focal coagu-
lative necrosis extending broadly from renal cortex and medulla.
FIG. 11. Effects of ethanol. Focal coagulative necrosis. There
were skip areas of viable tissue in three of six lesions (50%).
metaplasia in all pigs, which is a common finding in this ani-
mal.43
Cryotherapy and bleeding: Cozzi and associates41 re-
ported 5 of 10 animals treated by cryoablation with 5-mm
probes had subsequent hemorrhage following thaw. Tampon-
ade of the tract was generally all that was necessary for he-
mostasis.28,34,35,39,41,43,44 In contrast, perhaps because of the
small size of the cryoprobes used in our study, we did not en-
counter any bleeding in any of our animals.
Cryotherapy and imaging: Renal ultrasonography effec-
tively shows the formation of the anterior portion of the ice-
ball, and because the cryolesion is spherical, its posterior ex-
tent can be inferred. Computed tomography has also been used
to guide cryotherapy45,46; the iceball appears as a well-mar-
ginated low-attenuation area. Magnetic resonance imaging with
an integrated guidance mechanism and MR-compatible cry-
oprobes can be used to show the iceball in its entirety25,47–51
and can provide a three-dimensional image of the developing
iceball. Also, the area of an iceball will no longer enhance with
gadolinium.47–53 On T1-weighted images, all cryotherapy le-
sions are isointense with an occasional hyperintense rim; on T2-
weighted images, the lesions are hypointense. An MRI scan 1
month after surgery demonstrates an increase in signal inten-
sity on both T1- and T2-weighted images but no enhancement.
In follow-up after cryotherapy, sequential MRI scans are ex-
cellent for the detection of any changes in the treated lesion.52
Application of cryotherapy:Cryotherapy of the kidney may
be delivered percutaneously or laparoscopically (Table 2). The
former method, first described in 1995 by Uchida and col-
leagues,54 was most recently updated and expanded by Shin-
gleton and coworkers,55 who imaged the lesion with an open
MR scanner. Laparoscopic renal cryoablation has received a lot
of attention lately from several centers. While far more inva-
sive than a percutaneous approach, it has several potential ben-
efits: ability to observe the margins of the iceball, ability to dis-
place and protect adjacent structures, and potential control of
hemorrhage. The clinical work of various investigators is sum-
marized in Table 3. It has been proposed that a transperitoneal
approach is better suited for anterior renal lesions; whereas a
retroperitoneal approach affords better access to tumors on the
posterior aspect of the kidney.56 The entire laparoscopic pro-
cedure is monitored with an articulating laparoscopic transducer
to ensure proper treatment of the tumor.56–60 Injury to the
bowel29 and stricture of the ureteropelvic junction30 have been
reported after open cryoablation in a canine model; however,
this has yet to occur clinically. Nonetheless, extreme care must
be taken to monitor the iceball continuously under both lapa-
roscopic vision and ultrasound imaging.
Microwave thermotherapy
Microwaves are the 300- to 3000-MHz range of the electro-
magnetic spectrum.61 All waves in the microwave spectrum can
interact with tissue and produce heat. For example, the Prosta-
tron (EDAP-Technomed) uses a 1296-MHz frequency, while
the T3 (Urologix) and Urowave (Dornier) use a 915-MHz fre-
quency.62 For surgical therapy, the microwaves are emitted
from a flexible antenna. Microwave energy can be used for co-
agulation as well as ablation; it has been employed for hemo-
stasis in open63 and laparoscopic64–67 partial nephrectomies.
The flexibility of the microwave antenna and the coagulative
nature of thermotherapy make the approach ideal for renal ab-
lation. The depth of tissue penetration can be altered by chang-
ing the frequency of the energy source.
Mechanism of action: The microwaves emitted from the an-
tenna (e.g., needle electrode) pass through the tissue and cre-
ate a rapidly alternating electromagnetic field that leads to os-
cillation of free charges (electrons and ions). As the water
molecules follow the changing polarity of the field, the in-
creased kinetic energy is transformed into heat, resulting in co-
agulation necrosis.61 The tissue temperatures in a microwave
field depend, not only on the energy imparted to the tissue, but
also on the thermal conduction and convection, which are re-
lated to tissue perfusion and tissue heterogeneity.68 The depth
of penetration is inversely related to the frequency and the wa-
ter content of the targeted tissue.69 At any time, tissue pene-
tration also varies directly with temperature. Thus, accurate tis-
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FIG. 12. Effects of ethanol with monopolar RF energy. Com-
plete coagulative necrosis extends from renal cortex and
medulla to renal pelvis.
FIG. 13. Effects of acetic acid. There was complete coagu-
lative necrosis with 100% cell kill in all lesions. Lesions dis-
play central zone of necrosis and hemorrhage.
sue temperature monitoring is paramount to successful and safe
MT. Maintaining intralesional temperatures at .45°C while si-
multaneously keeping the surrounding temperatures ,45°C
will cause coagulation necrosis in the targeted lesion while pre-
serving the surrounding normal tissue.70–73
Temperature correlation: At 40°C, cellular homeostasis is
maintained; however, at 42° to 45°C (hyperthermia), cells be-
come susceptible to damage.74,75 However, even prolonged
heating at these temperatures will not result in complete cell
death in a given volume of tissue. When temperatures are in-
creased further, to $46°C (i.e., thermotherapy) for 60 minutes,
irreversible cellular damage will occur.76 Increasing the tem-
perature only a few degrees further, to 50° to 52°C, markedly
shortens the required treatment time (4–6 minutes).77 Between
60° and 100°C, nearly instantaneous coagulation of cytosolic
and mitochondrial enzymes and nucleic acid–histone com-
plexes occurs.78 After thermal damage, cells undergo coagula-
tive necrosis over the course of several days. Temperatures
.105°C result in tissue boiling, vaporization, and carboniza-
tion. This process actually retards the spread of necrosis be-
cause of a decrease in energy transmission.77 Thus, for ablative
thermotherapy, the goal is to achieve and maintain a 50° to
100°C range within the entire target volume without causing
carbonization. In addition, tissue with increased blood flow may
be less susceptible to heat injury because of the heat-sink ef-
fect.79–82
Creation of bigger lesions: During microwave treatment,
tissue temperature is measured via fiberoptic thermosensors lo-
cated different distances from the microwave antenna. Ther-
motherapy with a quick rise in temperature (i.e., “heat shock”)
is more effective than slow heating, as the rapid rise in tem-
perature (in 4 to 6 minutes) causes early vascular thrombosis
and subsequent coagulation necrosis.83 Also, the rapid rise in
temperature precludes the inhibition of thermotherapy by va-
sodilatation and concomitant augmentation of the heat-sink ef-
fect.76 Lastly, the treatment times are reduced using the heat-
shock approach.84
Effect of different antennae: In addition to the microwave
generator’s power and the heat-shock strategy, the configuration
of the interstitial antenna is of significant importance for achiev-
ing adequate intralesional tissue temperatures.85 To achieve high
temperatures, the antenna must have minimal back heating and
reflected power.72,85,86 Monopole antennas (Prostatron) reflect
15% of their energy back to the antenna, so the energy absorbed
by tissue is less; in contrast, a dipole antenna reflects only 1%
of the energy.86 In the present study, we used a dipole antenna.
Also, proper function of the microwave antenna is dependent
on proper impedance matching, which in turn is dependent on
the dielectric properties of the tissue surrounding the antenna.
Highly perfused tissues, such as the kidney, have a high water
content; water has a high dielectric constant. If water is driven
out of the tissue by excessive heating, the dielectric constant
will change dramatically, causing the resonance of the antenna
to move upward beyond the capability of the antenna to achieve
efficient transfer of energy.
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FIG. 14. Effects of acetic acid and monopolar RF energy. Le-
sions were irregular, larger on surface of kidney and smaller
toward renal pelvis. There was complete necrosis without skip
areas.
FIG. 15. Gross appearance of heat-based RF (RITA)-induced
lesion. Lesions are circular and pale yellow. Within lesion, there
is loss of corticomedullary junction.
Literature review: microwave renal ablation: The first ex-
perimental studies on renal ablative MT were performed in rab-
bit kidneys. Kigure and associates reported on the laparoscopic
application of MT in an in vivo VX-2 tumor model implanted
in rabbit kidneys (Table 4).67 Their report showed no differ-
ence in survival between rabbits treated with laparoscopic MT
and those undergoing open nephrectomy. The initial studies
demonstrated the ability of MT to cause coagulative necrosis 5
mm from the electrode; temperatures .60°C were routinely
recorded.63 Furthermore, there was no significant elevation of
temperature 2 cm from the electrode. Later studies of percuta-
neous ultrasound-guided treatment of implanted VX-2 carci-
noma with MT confirmed the effectiveness of this modality.67
Radiofrequency energy (monopolar and bipolar)
Clark in 1911 first published on the use of RF energy (high-
frequency alternating current) to cut and coagulate living tis-
sue, including bladder tumors.87 Radiofrequency energy be-
came popular in surgery after the pioneering work of Harvey
Cushing, a neurosurgeon, and W. T. Bovie, a physicist.88 Ad-
vances have been made in the methodology of modulating the
RF waveform, controlling the power output, and monitoring the
electrode tip temperature. These changes have enabled wider
application of RF current in all surgical specialties.
The equipment required for RF ablation is a generator, a
probe, and a grounding pad; in addition, for ablation therapy,
it is recommend to have available a data recorder (computer
with software to record thermocouple temperatures, impedance,
and the amount of power and energy delivered). The RF gen-
erators are similar in appearance to those in common use for
electrosurgical cutting and coagulation in today’s operating
room. Most RF generators deliver a 300-kHz to 500-MHz con-
tinuous unmodulated sinusoidal waveform and are designed to
reduce interference from other electronic equipment.
Soft-tissue ablation using RF energy has been widely prac-
ticed during open and endoscopic procedures. The objective is
to create the largest lesion using the smallest possible electrode
size and minimum RF power. This can be achieved by mini-
mizing the power density around the electrode, which can be
accomplished by increasing the conductivity of the tissue (i.e.,
reducing the tissue impedance) surrounding the electrode. The
goal of RF tumor ablation is to treat for 5 mm beyond the tar-
geted lesion in order to achieve satisfactory margins.
Mechanism of action: The RF energy travels from the ac-
tive (positive) electrode to return to either the patient’s ground-
ing plate (negative) electrode (monopolar) or a negative elec-
trode built into the delivery needle (bipolar).89–92 The RF
current flows from the needle electrode into the surrounding
tissue on its way to the grounding pad; this causes agitation of
water molecules, which creates molecular friction at the cellu-
lar level, thereby producing heat.93 The cellular fluid in the tis-
sue (0.9% saline) readily conducts the RF current; however,
over time, the tissue impedance increases. Eventually, the cel-
lular and extracellular fluid reach the boiling point, the end re-
sult of which is tissue necrosis secondary to protein denatura-
tion, desiccation, and coagulation. This form of RF application
differs from direct heating of tissue by a “hot” probe, as would
occur with electrocautery; instead, the tissue surrounding the
electrode, rather than the electrode itself, is the primary source
of heat production.93,94 Animal studies have shown that RF en-
ergy can be delivered with an adequate density per unit volume
of neoplastic tissue.89
As the target tissue temperature increases to approximately
50°C, cellular proteins become denatured, and the cellular lipid
component begins to melt, leading to disintegration of cell
membranes and irreversible tissue destruction (normal tissue).
It is generally thought that temperatures .70° to 80°C need to
be reached for tumor ablation. Both a rapid fall-off of energy
from the probe and poor heat conduction adversely affect the
lesion size. The heat energy that can be deposited in the tissues
is limited by tissue boiling and vaporization at higher temper-
atures (.105°C). When tissue vaporizes, gas is formed, which
both increases tissue impedance, thereby reducing the extent of
heat spread in the tissue, and serves as an insulator, thereby de-
creasing heat and current spread.
With monopolar RF energy, a large portion of the patient be-
comes part of the circuit as electrons flow from the point at
which they are delivered by the needle electrode to the ground
or return plate. The risk of accidental burns is higher because
electrons seek the path of least resistance, and if the return pad
is faulty, the current may exit other areas of the body. In con-
trast, bipolar RF is essentially a miniaturized isolated circuit,
in which the active electrode (source of the current) and re-
ceiving electrode are located on the same needle. The current
therefore does not travel through the body to a return plate but
only through the tissue between the electrodes. The patient does
not become a part of the circuit: only the tissue between the
electrodes does. Bipolar systems have greatly reduced the haz-
ards secondary to stray current.
Variables: There have been a number of approaches to cre-
ating larger RF lesions: increasing the effective size of the elec-
trode,90,91,95,96 cooling the electrode tip with a circulating fluid,
using multiple probes or multiple-prong electrodes, and lower-
ing the impedance of the tissue surrounding the electrode by
infusing the periprobe area with a conducting solution.90,97
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FIG. 16. Histologic effects of heat-based RF (RITA)-induced
lesion. Complete necrosis with no skip areas is seen to extend
broadly from renal cortex and medulla. Microscopic margin of
lesion is slightly dentate. There is 2- to 3-mm rim of inflam-
mation around area of necrosis.
Also, the time of application directly impacts the extent of the
lesion created (Table 5).
Increasing RF energy deposition: probe number: The use of
multiple probes or of a single probe with multiple tines greatly
increases the extent of ablated tissue. In an in vivo study on calf
livers, Goldberg and colleagues98 produced uniform spherical
necrosis using three or four probes placed in close proximity;
lesions measured 3.0 6 0.2 cm and 3.2 6 0.1 cm, respectively.
Probes produced overlapping lesions if they were within 1.5 cm
of each other.98
Improving RF energy delivery to the tissue: Wet RF: By in-
fusing a small quantity of isotonic saline into the targeted tis-
sue via the needle electrode, the conductivity of the tissue can
be improved, allowing RF energy to be conducted for a longer
time and hence to cause a larger zone of necrosis.89,99 The in-
fusion of saline blunts the rise in tissue impedance by increas-
ing the conductivity of the extracellular fluid.99–102
In a study comparing conventional RF (without saline per-
fusion) and RF with saline perfusion (14.6% sodium chloride)
in the dog prostate, Hoey and colleagues103 demonstrated that
RF with saline pretreatment created bigger lesions (mean 8.5
cm) than conventional RF (mean 0.34 cm).89,91 Usually, a hy-
pertonic saline infusion of only 1 mL/min (wet RF) is infused
during the RF activation.89,103–106 By increasing the duration
of RF energy (with power and electrolyte concentration held
constant), the size of the lesion can be extended to several cen-
timeters.105
Tissue conductivity can be further increased by infusing hy-
pertonic saline (23.6%). The advantage of using hypertonic
saline is that smaller amounts of fluid can be infused (e.g., 4
mL). This prevents the creation of too large a lesion.
One drawback of using saline is that it has the tendency to
leak around the RF needle as it is infused. In order to limit this
problem, we created a hypertonic saline conducting gel. With
the gel, the lesion is more localized and flow back along the
needle also appears to be decreased.
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TABLE 2. ANIMAL STUDIES OF CRYOTHERAPY OF KIDNEY
Series (year) Subjects Approach Technique Pertinent aspects
Bush et al142 (1964) Rat Open Direct Renal function recovery after
submersion rapid cooling with liquid
in liquid nitrogen
nitrogen
Breining et al143 (1974) Rats Open Direct Histologic, histochemical, and
contact autoradiographic analysis
Helpap et al144 (1979) Rats Open Direct Immunologic response
contact
(6.5 mm2)
Sindelar et al42 (1981) Rat Open Puncture Ultrastructural changes during
renal cryoablation and
monitoring of iceball
Barone and Rodgers145 (1988) Rabbits Open Puncture Functional and morphologic
effects
Onik et al146 (1993) Dog Open Puncture Ultrasound characteristics
Stephenson et al40 (1996) Dogs Open, Contact Laparoscopic cryoablation
laparoscopic (single freeze cycle)
Cozzi et al41 (1996) Sheep Open Puncture Open cryoablation (single
freeze cycle)
Gill et al29 (1996) Pigs Laparoscopic Puncture Laparoscopic/percutaneous
cryoablation
Chosy et al28 (1996) Pigs Open Puncture Thermosensor-monitored
cryotherapy
Nakada et al39 (1997) Pigs Laparoscopic Puncture Puncture v contact
Campbell et al30 (1998) Dogs Open Puncture Impact of renal artery
clamping
Sung et al147 (1999) Pigs Open Puncture Impact of cryoablation on
collecting system
Chen et al148 (1999) Pigs Open Puncture Doppler flow and power
Doppler studies after
cryoablation
Nakada et al149 (1999) Rabbit Open Puncture Therapeutic efficacy in
implanted VX2 tumor
model v nephrectomy
Present study (2001) Porcine Laparoscopic Puncture Feasibility of using ultrasmall
(1.4-mm) cryoprobes to
reduced hemorrhage and
enhance percutaneous
therapy
In our study, the conductive gel provided efficient RF en-
ergy transfer while simultaneously cooling the electrode tip.
The resultant effect was much larger lesions without increas-
ing the size of the electrode. The largest lesions were achieved
using hypertonic saline gel with monopolar RF (27 6 4.3 mm)
followed by hypertonic saline gel with bipolar RF (21 6 2 mm).
There were no skip areas in these lesions.
Imaging: Using ultrasound, RF was seen as a hyperechoic
area, which slowly disappeared over 30 minutes following RF
treatment.107 A good correlation has been shown between hy-
perechoic areas and subsequent necrosis; however, the edge of
the echogenic region remained irregular and ill defined.107 On
contrast-enhanced CT or MRI, the chronic changes of RF (i.e.,
coagulation necrosis) appear as a new area of nonenhancement;
there is often a 2- to 3-mm peripheral enhancing rim seen both
on gadolinium-enhanced MRI and, albeit more rarely, contrast-
enhanced CT. This area has been shown by pathologic evalua-
tion to correlate with a rim of granulation tissue. Indeed, ab-
sence of a well-defined rim may be indicative of residual tumor
and necessitates biopsy.
Literature review: RF for renal ablation: Zlotta and col-
leagues first described use of RF for renal tumors (Tables 6 and
7). Initially, they used RF on nephrectomy specimens immedi-
ately ex vivo and then did in vivo RF for ,3-cm lesions just
prior to nephrectomy.108,109 The RF lesions were 2.2 3 3 3 2.5
cm. Histologic examination revealed intense stromal and ep-
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TABLE 3. CLINICAL STUDIES OF CRYOTHERAPY OF KIDNEY
Series (year) Subjects (no.) Approach Technique Pertinent aspects
Uchida et al54 (1995) Dogs, Percutaneous Puncture Percutaneous renal
human cryoablation;
(2) embolized kidney to prevent
rewarming from circulating
blood showing increased
efficacy of tumor kill
Delworth et al150 (1996) Human Open Puncture Open renal cryoablation of a
(2) central RCC, with success at
1-month follow-up.
Gill et al56 (1998) Human Laparoscopic Puncture Laparoscopic renal
(10) cryoablation
McGinnis et al151 (1998) Pigs Laparoscopic Puncture Laparoscopic cryoablation
Human (retroperitoneal) is feasible
(3)
Bishoff et al38 (1999) Pigs Laparoscopic Puncture Pig laparoscopic cryoablation
Human (N 5 12); human
(8) laparoscopic cryoablation
(N 5 8)
Orihuela et al152 (1999) Human Open Puncture Prenephrectomy cryoablation
(15) (just before with artery clamping has
nephrectomy) no effect
Gill et al153 (2000) Human Laparoscopic Puncture Retroperitoneal and
(32) transperitoneal cryotherapy.
Postcryotherapy biopsies
used for follow-up at 3 and
6 months
Shingleton et al55 (2001) Human Percutaneous Puncture MRI-guided percutaneous
(20) cryotherapy (N 5 22)
Steinberg et al (Gill)154 Human Laparoscopic Puncture Retroperitoneal and
(2002) (36) transperitoneal cryotherapy.
22 (61%) Postcryotherapy biopsies
positive used for follow-up at 3 and
biopsy 6 months; 24 patients .4-
year follow-up. Biopsy at
6 months negative; 1 (2%)
had enhancing mass at 18
months and biopsy-
confirmed recurrent RCC
Shingleton et al155 (2003) Human Percutaneous Puncture Renal tumor #5 cm
(N 5 70) (open MRI) Triple freeze and thaw cycle,
with 70 with 5-mm margin, 2–4
lesions probes used
Follow-up 2 years (1–3.5
years)
Retreatment 13%
ithelial edema, as well as marked pyknosis and peripheral hem-
orrhage in all lesions. Pathologic review showed extensive co-
agulative necrosis of the lesion with no residual tumor cells.
No damage was noted beyond the targeted area. Normal renal
cells were affected in much the same way as tumor cells. Sub-
sequently, McGovern and associates110 treated renal tumors
percutaneously with standard RF with the patients under intra-
venous sedation and saw no evidence of lesion enhancement at
3-month follow-up by CT scans. Sullman and colleagues111
treated two patients with renal masses using MRI-guided RF
ablation percutaneously. Pavlovich and Walther and their
coworkers reported percutaneous treatment of two patients with
Von Hippel-Lindau disease using RF ablation under CT and ul-
trasound guidance.112,113 Lesions as large as 2.9 cm were ab-
lated. Follow-up CT scans showed no lesion enhancement.
However, more recently, there have been three clinical stud-
ies114–117 showing persistence of some viable cells within the
tumor after RF. Our findings are compatible with these more
ominous observations of viable skip areas or peripheral viable
tumor. The dry RF techniques tested in our study produced cel-
lular necrosis on normal porcine renal parenchyma but left skip
areas in some of the lesions; however, the addition of hyper-
tonic saline conduction gel with both monopolar and bipolar
RF (i.e., wet RF) created larger lesions with complete necrosis.
This has been observed clinically as well when tumor was ab-
lated with wet RF before partial nephrectomy (Dr. J. Libertino,
personal communication).
Lastly, there is evidence that “cooled-tip” electrodes (con-
tinuous flow of ice-cold fluid in needle electrode) coupled
with a high-energy-output generator (220 W) preclude a sud-
den rise in impedance and thus may be more effective.118,119
At the National Cancer Institute, Walther and colleagues have
used a cooled-tip 200-W RFA generator (Radionics, Burling-
ton, MA) for renal radiofrequency ablation since 2001
(Marston Linehan, personal communication). A total of 8 and
12 hereditary-type renal tumors have been ablated percuta-
neously and laparoscopically. At a median follow-up of 384
days, none of the ablated tumors demonstrated contrast en-
hancement on CT imaging, so the patients are considered re-
currence free by CT criteria.
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TABLE 4. LITERATURE REVIEW OF MICROWAVE THERMOTHERAPY OF KIDNEY
Tissue
Series (year) Subjects (No.) Approach Size of lesion Pertinent aspects
Kigure et al63,156 Rabbit VX 2 Percutaneous 5-mm area of 2450 MHz at 100 W for 30 s;
(1994, 1995) rabbit (ultrasound coagulation necrosis histologic examination
renal guided) (1 week and 8 revealed complete
tumor weeks) coagulation necrosis
(18)
Kigure et al67 Rabbit VX 2 Laparoscopic 5–6-mm coagulative 2450-MHz microwaves at
(1996) rabbit necrosis around 100 W for 30 s
renal probe, which was
tumor further surrounded
(10) by 5-mm area of
scattered
hemorrhage (2
weeks)
Present study Pig Normal Laparoscopic 22-mm area of 915 MHz at 20 W for 15
(2001) kidney coagulative necrosis min; histologic examination
(12) (1 week) revealed complete
coagulation necrosis.
Clinically, microwave thermotherapy has been used to control hemostasis during partial nephrectomy,157,158 but complete ab-
lation of the lesion has not been performed. Urologix has introduced new antennae, and a different setting creates much larger
lesion (Eric Rudie, personal communication).
TABLE 5. RF PARAMETERS AFFECTING SIZE OF LESION
Parameters for lesion Power (W), electrode size (area), treatment time, tissue
formation impedance (V), power density (power area), energy
density (power density 3 treatment time)
Power density (PD) Higher PD creates rapid, albeit smaller, lesions, while lower
(power/area) PD creates larger lesions over time.
Tissue impedance Higher impedance (less conduction) creates smaller lesions;
lower impedance allows bigger lesions to be created.
Electrode size Smaller electrodes create smaller lesions; bigger electrodes
create larger lesions.
Treatment time Shorter treatment time creates a smaller lesion, while a
longer treatment time creates a larger lesion.
Hypertonic saline gel
In the early 1990s, hypertonic saline infusion was used to
treat benign liver cysts. Hypertonic saline has recently been
used to treat hepatocellular carcinoma (HCC),120 liver cysts,121
and benign prostatic tissue. Likewise, it has been used to scle-
rose telangiectasias.122–126 The most recent interest in the use
of hypertonic saline injection has been as an adjunct to RF en-
ergy; the injected hypertonic saline allows greater spread of the
energy. In this regard, much work has been done by Hoey, Lev-
eillee, and colleagues in the prostate.
Mechanism of action: Normal and hypertonic (14.6%)
saline have been used.122,105 Hypertonic saline is helpful as it
has a direct cytotoxic effect by virtue of its osmotic action,
which causes cellular dehydration. We have used 23.4% saline
in our studies, as the higher concentration minimizes the vol-
ume needed (e.g., 4 mL instead of 15–20 mL).
Renal ablation: The present study is the first to use hyper-
tonic saline as a stand-alone therapeutic agent for renal abla-
tion. We first characterized and compared the volume, regular-
ity, and histologic manifestations of renal lesions produced by
the injection of 23.4% saline immediately postoperatively and
at 48 hours. In this group of animals, a small quantity of indigo
carmine was added to each injected volume to delineate the ex-
tent of the agent’s diffusion. There was uncontrolled leakage
from the needle tract; accordingly, we designed a hypertonic
saline gel to limit the leakage. However, the lesions created
with hypertonic saline gel alone remained small (2.33 6 0.33
mm) and were characterized by the presence of skip areas of
viable tissue.
Ethanol gel with or without single monopolar and
bipolar RF
Ethanol has been employed in transarterial embolization in
patients with renal-cell carcinoma since the early 1980s127–129
or just prior to planned radical nephrectomy to reduce collat-
eral flow through tumor vessels.127–129 Iaccarino used percuta-
neous ethanol injection into the renal vasculature (transarterial)
for renal hypertension in patients unsuitable for angioplasty or
surgery. Similarly, ethanol injection has been used for many
years for renal cyst sclerotherapy.
Ethanol was first used for ablation of a parenchymal hepatic
tumor in 1983 in Japan; it was administered under real-time ul-
trasound guidance.130 Absolute ethanol injection resulted in ex-
tensive tumor destruction and marked reduction in tumor vas-
cularity.131 Since then, the use of hepatic tumor ethanol
injection has become more widespread; however, to date, there
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TABLE 6. REVIEW OF RF RENAL ABLATION (ANIMAL STUDIES)
Subjects
Series (year) (No.) Tissue Approach Lesion size Pertinent aspects
Polascik et al159 Rabbit (9) VX-2 Open under US 1.4 3 1 cm Interstitial single-augmented RF
(1999) tumor guidance (30 sec) of nonmalignant (control) and
1.8 3 1.5 cm malignant (the VX2 tumor)
(45 sec) tissues under US guidance in
renal tissue in a rabbit model
50 W at 500 KHz for 30 to
45 sec
Merkle et al160 Pig (3) Normal Percutaneous 7–14 mm 120 W at 500 KHz for 10 min
(1999) tissue (MR guidance)
Patel et al106 Rabbit (48) Normal Laparoscopic; 7 cm (1 min) Interstitial saline-augmented RF
(2000) tissue needle placed 10 cm (2 min) 50 W at 475 KHz for 1 or
percutaneously 2 min
Nakada et al161 Rabbit (30) VX 2 tumor Open N/A Therapeutic efficacy in
(2000) implanted in implanted VX2 tumor model
kidney with multitine 12-gauge RF
probe; 90°C for 8 min (RITA
Medical) compared with
nephrectomy for treatment;
therapies found to be equally
efficacious.
Gill et al162,163 Pig: acute Normal Laparoscopic 3 3 1.5 (day 7) 55 W for 5 min then increased
(2000) (6) and tissue (acute) Lesion incrementally by 10 W every
chronic (5) Percutaneous reabsorbed minute until impedance of
(chronic) and replaced 100 V was reached. Multitine
by scar at 1 probe. Complete necrosis.
month
Present study Pig (20) Parenchyma Laparoscopic Monopolar Both dry and wet (i.e., infusion
(2001) 8.14 3 6.57 3 of 23.4% saline gel) via
7.43 mm single probe
Bipolar
7.44 3 6.44 3 
6.22 mm
TABLE 7. REVIEW OF RF RENAL TUMOR ABLATION (HUMAN STUDIES)
Lesion size
Series (year) No. Approach (cm) Pertinent aspects
Hall et al164 1 Percutaneous Combined embolization (interlobar
(2000) (CT guided) artery) and RF. Three RF
activations were given: 60 W/4 min,
60 W/3 min, 50 W/5 min.
Sullmann et al111 2 Percutaneous 2–3.5 1.5 amp for 30 min
(2000) (MR guided)
Pavlovich et al112 2 (VHL or Percutaneous 2.4–2.9 26 w, 480 KHz for 5 minutes
(2000) HPRC)a (combined (temperature (95 to 105°C)
ultrasound and
CT guided)
Geravis et al165 9 (7 biopsy Percutaneous ,3 (1RF cycle) Free of enhancement
(2000) proven; 2
enhancing .3 (.1 RF 4/6 free of enhancement
lesions; mean cycle) Follow-up 10.3 months
3.3 cm Cool-tip electrode
(1.2–5 cm) 1500–1800 milliamp for 1 min
Pulsing to prevent sudden rise
impedance
Pavlovich et al166 21 Percutaneous 2 RF cycles 19/24 tumors ceased to enhance
(2002) 19/24 temp .70°C
5/24 temp ,70°C
(2-month CT
data presented)
Walther et al113 Phase II study Open Tumor ,5 cm 10/11 lesions completely treated (26
(2000) in 4 pts with treated W, 480 KHz for 5 min; temp 95°
11 tumors to 105°C)
Zlotta et al108,109 Ex vivo (4); Ex vivo (after 2.2 3 3 3 2.5 Ex vivo, maximum temperature at
(1996, 1997) in vivo (2) kidney removed) needle tip ranged from 84° to 130°C
and in vivo (just with 10 to 14 W applied over 10 to
before open 14 min
nephrectomy)
McGovern et al110 1 Percutaneous Case report Tumor heated to 90°C for 1 min at
(1999) 500 KHz followed by 1200
milliamp for 12 min
Matlaga et al167 10 (tumor Open surgery, 3.2 (1.4–8) 8 completely ablated with 200 W
(2002) excised after ultrasound for 12 min
ablation) guided Pulsing to prevent sudden rise in
impedance
18-gauge probe (one probe for tumor
,2 cm and three probes for tumor
.2 cm
Cool-tip electrode
Rendon et al117 10 (9 biopsy Open surgery, 2.4 1/5 acute group totally ablated
(2002) proven; 1 CT or US 3/6 delayed group totally ablated
angiomyoa) guided 2 cycles applied
Acue (N 5 4) LeVeen electrode
nephrectomy (Radiotherapeutics)
after treatment;
chronic (N 5 6)
nephrectomy
at 1 week
Michaels et al168 15 pts with 20 Open (ablation 2.4 (1.5–3.5) 110 watts at 460 KHz for 6–16
(2002) tumors before partial minutes (heated to 90–110°C)
nephrectomy;
US monitoring (RITA StarBurst XL probe, RITA
Medical, California)
De Baere et al119 5 Percutaneous 3.3 (3.0–4.0) 480 KHz generator at 200 W; 15-min 
(2002) CT or US treatment cycle; one or two treatment
cycles
Cool-tip electrode
Gervais et al118 34 pts with 42 Percutaneous 3.2 (1.1–5) 200 W generator; 12-min treatment
(2003) tumors cycle
Cool-tip electrode
Mean follow-up 13.2 mos
aVHL 5 Von Hippel-Lindau disease; HPRC 5 hereditary papillary renal-cell carcinoma; angiomyo 5 angiomyolipoma.
are no data on using this modality for the treatment of small
solid renal tumors.
Mechanism of action: Animal studies have shown the toxic
effects of alcohol at the cellular level.132–137 Specifically, al-
cohol diffuses into cells and produces an immediate coagula-
tion necrosis secondary to dehydration, membrane lysis, and
protein denaturation. The chronic effects of this exposure are
fibrosis and small-vessel occlusion/thrombosis. The end result
is marked cell necrosis.
Renal ablation: To the best of our knowledge, ours is the first
report of the use of direct ethanol injection to ablate renal pa-
renchyma. We characterized and compared the volume, regular-
ity, and histologic appearance of renal lesions produced by in-
jection of 95% ethanol immediately postoperatively and at 48
hours. In this group of animals, a small quantity of indigo carmine
was added to each injected volume to delineate the extent of the
agent’s diffusion. Our initial results showed that ethanol diffused
into the tissues in an uncontrolled manner; also, as with hyper-
tonic saline, there was marked leakage of the ethanol back along
the needle tract, with subsequent injury to surrounding tissue. Ac-
cordingly, we formulated ethanol into a gel (95% alcohol and an
inactive polymer thickening agent). The gel injections were more
contained within the renal tissue and produced less leakage along
the needle tract. Ethanol gel alone produced lesions of reason-
able size; however, these lesions contained skip areas of viable
cells, thereby negating ethanol infusion alone as an effective ab-
lative modality in the kidney. However, the lesion was twofold
to threefold larger when ethanol was combined with monopolar
or bipolar RF (50 W and 475 kHz for 5 minutes).
Acetic acid gel with or without monopolar 
and bipolar RF
Ohnishi and colleagues138 reported that acetic acid had a
stronger cytotoxic effect than pure ethanol in both animal stud-
ies and human studies of HCC. These investigators treated small
(,3-cm) HCCs in 25 patients with multiple acetic acid injec-
tions with good therapeutic effect. The clinical results were fol-
lowed with CT and fine-needle biopsy in all patients. Two pa-
tients eventually underwent partial hepatic resection. The 1-year
survival rate among the 23 patients who did not undergo sur-
gical treatment was 100%; the 2-year survival rate was 92%.
Mechanism of action: Acetic acid penetrates cells and can
dissolve lipids and extract collagen.138,139 Experiments with rats
have shown that the necrotizing effect of acetic acid on liver
cells is enhanced by increasing its concentration to a maximum
of 50%; of note, its effect at a concentration of 15% was equal
to that of absolute ethanol,138 and at 50%, it was three times as
effective than ethanol.138 The use of the higher concentration
of acetic acid (i.e., 50%) is preferable because it reduces the
number of treatment sessions required.140 A notable difference
between acetic acid and ethanol is that the former, because of
its low pH, appears to have good penetration into cancer cells
in the tumor’s capsule and into intratumoral septa; as a result,
intratumoral fibers swell, and there is dissociation of intermol-
ecular cross-links of collagen in the septa. Therefore, the num-
ber of treatment sessions may be fewer with acetic acid while
the incidence of local recurrence is reduced.141 Once injected
into a tumor, acetic acid takes from several hours to a day to
solubilize interstitial collagen (type I and III) and basement
membrane collagen (type IV).
Renal ablation: Acetic acid has not been used previously
for renal ablation. We first characterized and compared the vol-
ume, regularity, and histologic manifestations of renal lesions
produced by the injection of 50% acetic acid immediately post-
operatively and at 48 hours. Our initial results showed that
acetic acid diffused into the tissues in an uncontrolled manner.
It also leaked back along the needle tract and thus damaged sur-
rounding tissues. Accordingly, we formulated a gel (50% acetic
acid and an inactive polymer thickening agent). The injected
gel remained more contained in the tissues. Acetic acid injec-
tions created an area of complete necrosis that was much larger
than the volume injected; these lesions were also considerably
larger than those created with hypertonic saline or ethanol. This
observation would be compatible with the action of acetic acid,
which is to dissolve cell membranes.
We further characterized whether RF with acetic acid could
extend the zone of complete necrosis. Acetic acid gel with
monopolar or bipolar RF (RF setting 50 W and 510 kHz for 5
minutes) resulted in lesions that were larger than those formed
with acetic acid alone (20–21-mm v 14-mm length). There was
complete necrosis within all lesions created with acetic acid
plus RF.
CONCLUSIONS
The main aim of in situ needle ablation therapy is to use en-
ergy alone or combined with a noxious fluid to destroy an en-
tire tumor without damaging adjacent vital structures. In this
study, we looked at the majority of the available modalities for
needle ablation: cryotherapy; microwave technology; RF, both
dry and wet, using monopolar and bipolar needles; and chemoab-
lation alone or combined with RF using hypertonic saline, etha-
nol, or acetic acid. With regard to the latter, we found that a
unique gel formulation limited leakage of the chemoablative sub-
stance while maintaining the substances’ noxious and conduc-
tive characteristics.
From our studies, it appears that with current technology,
cryotherapy and multitine RF are the only modalities that offer
complete necrosis within the sphere of treatment while allow-
ing the surgeon to observe the delivery of the treatment ultra-
sonically. Microwave therapy, acetic acid injection, and
monopolar or bipolar RF plus hypertonic saline or with acetic
acid also create a lesion with complete necrosis; however, none
of these lesions can at present be monitored accurately with
real-time imaging. Of similar importance is that in our study,
single-needle RF alone, both monopolar and bipolar, as well as
ethanol or hypertonic saline alone produced lesions with in-
complete necrosis (i.e., skip areas of viable cells).
In this new millennium, further improvements in needle abla-
tive technology may ultimately lead to the routine outpatient
treatment of most renal-cell cancers in the 1- to 4-cm range. Ad-
vances of this nature are completely in line with the concept that
in a technologically advanced society, standard open surgical ex-
tirpation of most small cancers should no longer be necessary.
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